At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 862 enrolled
Drug / intervention
Astepro Nasal Spray (0.1% azelastine hydrochloride) +1 moredrug
Likely dose
Astepro Nasal Spray (0.1% azelastine hydrochloride) 548 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Astepro Nasal Spray (0.1% azelastine hydrochloride) and Astelin Nasal Spray (0.1% azelastine hydrochloride) for Chronic Allergic Rhinitis and Nonallergic Rhinitis. Completed, enrolled 862 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Allergic Rhinitis, Nonallergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
Primary CompletionDec 2007
First PostedOct 2008
TodayJul 2026
First PostedOct 31, 2008
Enrollment StartJul 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.7 years ago
Interventions
Astepro Nasal Spray (0.1% azelastine hydrochloride)drug
548 mcg (2 sprays per nostril) twice a day
Astelin Nasal Spray (0.1% azelastine hydrochloride)drug
548 mcg (2 sprays per nostril) twice a day